The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial:

JUPITER is a completed, randomized, double-blind, placebo-controlled trial of rosuvastatin 20 mg daily in the prevention of cardiovascular disease. Men who were at least 50 years old and women at least 60 years old were eligible for the trial if they did not have preexisting cardiovascular disease or diabetes, and had a low density lipoprotein cholesterol < 130 mg/dL and C-reactive protein ≥ 2.0 mg/L. JUPITER enrolled and randomized 17,802 subjects who were then followed for a median of 1.9 years (40, 41).


Return to the Cohorts


The BiomarCaRE project was co-funded by the European Community´s Seventh Framework Programme (FP7/2007-2013) under grant agreement N° HEALTH-F2-2011-278913. Copyright © 2011-2020 BiomarCaRE.eu - All Rights Reserved